Hemoglobin | Daprodustat, n=133 | Darbepoetin Alfa, n=134 |
---|---|---|

Baseline Hgb, g/dl | ||

n | 133 | 134 |

Mean (SD) | 10.9 (0.8) | 10.8 (0.7) |

Mean Hgb during wk 40–52, g/dl | ||

n | 120 | 125 |

Mean (SD) | 10.9 (0.7) | 10.8 (0.6) |

Change from baseline (SD) | 0.0 (1.0) | 0.0 (0.8) |

Adjusted mean Hgb during wk 40–52, g/dl | ||

Adjusted mean (95% CI) | 10.9 (10.8 to 11.0) | 10.8 (10.7 to 11.0) |

Adjusted treatment difference (95% CI) for mean Hgb during wk 40–52 | 0.1 (−0.1 to 0.2) | |

No. (%) of participants with mean Hgb within target during wk 40–52^{a} | ||

n | 120 | 125 |

No. of participants (%) | 105 (88) | 113 (90) |

Change from baseline in mean Hgb during weeks 40–52 was performed in a

*post hoc*analysis. Adjusted values were estimated by a mixed model for repeated measures as specified in Statistical Analyses. ITT, intent-to-treat; Hgb, hemoglobin; 95% CI, 95% confidence interval.↵a Modified ITT population.